Novo Nordisk: acquires the US company Corvidia
(CercleFinance.com) - The Danish pharmaceutical group Novo Nordisk announced on Thursday that it has reached an agreement to acquire Corvidia Therapeutics, a US company specialised in the development of new drugs for heart and kidney diseases.
The laboratory explains that the takeover of this unlisted company is part of its strategy to increase its presence on the cardiovascular and metabolic diseases market, on which it already has a strong presence with its treatments for diabetes and obesity.
Corvidia is currently developing a drug to reduce the risk of cardiovascular incidents in patients with chronic kidney disease who also present arteriosclerotic cardiovascular symptoms.
Under the terms of the agreement, Novo Nordisk will pay 725 million dollars in cash to acquire the company, whose shareholders could receive a total of 2.1 billion dollars, depending on the achievement of certain regulatory and sales milestones.
Copyright (c) 2020 CercleFinance.com. All rights reserved.